<DOC>
	<DOCNO>NCT00493805</DOCNO>
	<brief_summary>This Phase 3b/4 , prospective , open-label , randomize , multicenter study peginterferon alfa-2b plus ribavirin participant chronic hepatitis C , genotype 1 . The study consist two part : ( 1 ) noninterventional arm ( HOMA IR &lt; = 2 ) ( 2 ) interventional arm ( HOMA IR &gt; 2 ) , HOMA IR insulin resistance index participant calculate fast insulin ( uU/mL ) x [ fast glucose ( mmol/L ) /22.5 ] . Participants noninterventional arm treat accord European labeling response rate evaluate Month 1 ( optional ) , 3 , 6 , 12 , follow . Participants interventional arm treat PEG-Intron 1.5 ug/kg ( subcutaneous ) weekly plus weight-based REBETOL 800-1400 mg ( oral capsule ) daily variable period depend response Week 12 : ( 1 ) HCV-RNA positive &lt; 2-log drop viral load , treatment discontinue ; ( 2 ) HCV-RNA positive &gt; = 2-log drop viral load ; participant randomize ( 1:1 ) Group A ( stop treatment Week 48 ) Group B ( stop treatment Week 72 ) ; ( 3 ) HCV-RNA negative , treatment change accord European labeling response rate evaluate Month 6 , 12 , follow . All participant go treatment Week 12 result HCV polymerase chain reaction ( PCR ) available ( maximum 4 week ) .</brief_summary>
	<brief_title>Study Response Chronic Hepatitis C ( CHC ) Participants Genotype 1 With Insulin Resistance Prolonged Treatment Duration Late Responders ( P04823/MK-4031-303 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>male female participant newly diagnose chronic hepatitis C age 1865 HCVRNA positive serum measure PCR Genotype 1 ALT level accord European labeling woman childbearing age , pregnancy must exclude prior entry study , use safe contraceptive device must document ; sexually active male participant must practice method contraception consider acceptable ( vasectomy , condom plus spermicide , plus relationship female partner practice acceptable method contraception ) Lab parameter : Hb : &gt; =12 g/dL ( woman ) &gt; = 13 g/dL ( men ) leukocytes &gt; = 3,000/µL thrombocyte &gt; = 100,000/µL PT/PTT/coagulation must within normal limit clinically acceptable investigator/sponsor Albumin must within normal limit clinically acceptable investigator/sponsor creatinine must within normal limit clinically acceptable investigator/sponsor uric acid must within normal limit clinically acceptable investigator/sponsor antinuclear antibody &lt; = 1:160 sign inform consent refusal woman childbearing age sexually active participant use safe contraceptive breastfeed woman cirrhosis stage B C accord ChildPugh sign decompensated liver disease confirm coinfection HIV HBV exist psychiatric comorbidity alcohol abuse active malignant disease suspicion history malignant disease within 5 previous year ( except adequately treat basal cell carcinoma ) exist psoriasis dermatological disorder treatment study drug within last 30 day uncontrolled underlying medical condition clinically significant ECG abnormality and/or significant cardiovascular dysfunction within last 6 month . In case suspect heart disease , cardiological examination require . liver disorder genesis study indication ( regard elevate iron level , participant manifest hemochromatosis exclude ) autoimmune disorder ( except LKMpositive participant ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>homeostasis model assessment insulin resistance</keyword>
</DOC>